Follow The Filings

COLL Collegium Pharmaceutical Inc.

Health Care, filed as COLLEGIUM PHARMACEUTICAL INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 1.1%
  • $6.6M
  • 1 add

In 2026 Q2 Third Avenue Management added to Collegium Pharmaceutical.

Who owns this now

Largest portfolio weights among holders, up to 1.1% (Third Avenue Management). Not free-float ownership.

  1. Third Avenue Management Add 1.1%

Who owns COLL

Sorted by value, long equity only, as of 2026 Q2.

History
Third Avenue Management 1.1%, was 0.84% Add +17.7% 182,645 $6.6M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by COLL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All COLL insider trades
  • None no insider bought on the open market
  • $2.4M sold by 5 insiders outside a trading plan
  • $4.8M sold by 3 insiders under 10b5-1 plans
  1. John Gordon Freund Director
    Sale
    $681 20 shares at $34.05 <0.1% of stake
    Traded May 18 Filed May 20
  2. John Gordon Freund Director
    Sale
    $143K 4,127 shares at $34.54 4.7% of stake
    Traded May 15 Filed May 18
  3. Nancy Lurker Director
    Sale
    $162K 4,500 shares at $35.97 20% of stake
    Traded May 13 Filed May 15
  4. Garen G Bohlin Director
    Sale
    $323K 8,700 shares at $37.18 12% of stake
    Traded May 11 Filed May 13
  5. David Dieter EVP & General Counsel
    Planned sale
    $488K 13,976 shares at $34.92 15% of stake
    Traded Mar 18 Filed Mar 20
  6. David Dieter EVP & General Counsel
    Planned sale
    $228K 6,224 shares at $36.65 6.4% of stake
    Traded Mar 9 Filed Mar 11
  7. Scott Dreyer EVP & Chief Commercial Officer
    Planned sale
    $2M 49,976 shares at $40.41 41% of stake
    Traded Mar 3 Filed Mar 5
  8. Scott Dreyer EVP & Chief Commercial Officer
    Planned sale
    $848K 17,600 shares at $48.17 15% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
  9. Rita J. Balice-Gordon Director
    Sale
    $172K 3,650 shares at $47.03 6.5% of stake
    Traded Dec 5, 2025 Filed Dec 9, 2025
  10. John A. Fallon Director
    Sale
    $1.6M 34,853 shares at $47.21 35% of stake
    Traded Nov 12, 2025 Filed Nov 14, 2025
  11. Colleen Tupper CFO
    Planned sale
    $1.2M 30,000 shares at $40.53 19% of stake
    Traded Nov 6, 2025 Filed Nov 7, 2025

Also filed in the last 12 months, not counted as buying or selling: 17 stock grants, 10 share withholdings for taxes, and 6 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 1.02
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G —
8-K 8.01
8-K 2.02,7.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G —
8-K/A 9.01
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 5.07
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 2.01,5.02,7.01,9.01
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q
DEF 14A
8-K 5.02
SCHEDULE 13G/A —
8-K 1.01,7.01,9.01

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $566.77M $631.45M $780.57M
Gross profit $326.17M $377.34M $463.26M
Gross margin * 57.5% 59.8% 59.3%
Net income $48.16M $69.19M $62.87M
Net margin * 8.5% 11.0% 8.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $537.6M $482.26M $691.41M
Total non-current assets * $0.606B $1.18B $0.965B
Total assets $1.14B $1.66B $1.66B
Total current liabilities $457.92M $509.51M $440.03M
Total non-current liabilities * $489.96M $925.24M $915.13M
Total equity $195.43M $228.84M $301.68M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $274.75M $204.98M $329.32M
Cash from investing -$70.81M -$287.76M -$63.53M
Cash from financing -$140.18M -$60.6M -$110.24M
Net change in cash * $63.76M -$143.38M $155.55M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf